EichorEICHOR
Condition: Her2 Metastatic Breast Cancer Mbc Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Her2 Metastatic Breast Cancer Mbc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT06033287HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Phase 2 · 7 location(s) · Abscint NV/SA · NCT06369831Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Phase 3 · 3 location(s) · Shanghai Yizhong Pharmaceutical Co., Ltd. · NCT06143553Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastat
NA · 1 location(s) · Washington University School of Medicine · NCT04968964Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Phase N/A · 1 location(s) · University of California, San Francisco · NCT06774027Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-
Phase 1 · 3 location(s) · ExpreS2ion Biotechnologies · NCT06746688HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT07441889HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Phase N/A · 1 location(s) · Renske Altena · NCT06830382A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Phase 2 · 3 location(s) · Reshma L. Mahtani, D.O. · NCT06263543ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast C
Phase 2 · 44 location(s) · ALX Oncology Inc. · NCT07007559Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metas
Phase N/A · 1 location(s) · European Institute of Oncology · NCT06762483Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treat
Phase 2 · 5 location(s) · Delcath Systems Inc. · NCT06875128Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2 · 11 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT04965766A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positiv
Phase N/A · 1 location(s) · AstraZeneca · NCT07743944
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.